Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms-Reference-Cited by-同舟云学术

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

Published:2019-11-25 Issue:12 Volume:25 Page:1839-1842
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Durham Benjamin H.,Lopez Rodrigo Estibaliz,Picarsic Jennifer^ORCID,Abramson David,Rotemberg Veronica,De Munck Steven,Pannecoucke Erwin,Lu Sydney X.,Pastore Alessandro^ORCID,Yoshimi Akihide^ORCID,Mandelker Diana,Ceyhan-Birsoy Ozge,Ulaner Gary A.,Walsh Michael,Yabe Mariko,Petrova-Drus Kseniya,Arcila Maria E.,Ladanyi Marc,Solit David B.^ORCID,Berger Michael F.,Hyman David M.^ORCID,Lacouture Mario E.,Erickson Caroline,Saganty Ruth,Ki Michelle,Dunkel Ira J.^ORCID,Santa-María López Vicente,Mora Jaume^ORCID,Haroche Julien,Emile Jean-Francois^ORCID,Decaux Olivier,Geissmann Frederic,Savvides Savvas N.,Drilon Alexander^ORCID,Diamond Eli L.^ORCID,Abdel-Wahab Omar^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0653-6.pdf

Reference28 articles.

1. Badalian-Very, G. et al. Blood 116, 1919–1923 (2010).

2. Chakraborty, R. et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124, 3007–3015 (2014).

3. Diamond, E. L. et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Dis. 6, 154–165 (2016).